Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandan HealthcareNSE:CHANDAN -4.01%17 ROE % is 13.13% as of Dec. 2025, which is 35% below its 10-year median of 20.10. GuruFocus rates NSE:CHANDAN with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, Chandan Healthcare ranks better than 75.88% on this metric.
The historical rank and industry rank for Chandan Healthcare's ROE % or its related term are showing as below:
NSE:CHANDAN'
s ROE % Range Over the Past 10 Years
Min: -4.62 Med: 20.1 Max: 47.5
Current: 10.05
During the past 4 years, Chandan Healthcare's highest ROE % was 47.50%. The lowest was -4.62%. And the median was 20.10%.
NSE:CHANDAN's ROE % is ranked better than 75.88% of 199
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.08
vs NSE:CHANDAN: 10.05
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Chandan Healthcare ROE % Related Terms
Chandan Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Chandan Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Chandan Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandan Healthcare ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chandan Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Chandan Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Chandan Healthcare (NSE:CHANDAN) has a ROE % of 13.13% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Chandan Healthcare and its competitors. This is 35% below median its historical median of 20.10. According to the industry distribution chart, Chandan Healthcare ranks #48 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 24.1%.
Is Chandan Healthcare's ROE % too high?
Chandan Healthcare's current ROE % of 13.13% is 35% below median its 10-year median of 20.10. Based on the distribution chart, Chandan Healthcare ranks #48 out of 199 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Chandan Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Chandan Healthcare's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chandan Healthcare ranks #48 out of 199 companies for ROE %. This places Chandan Healthcare in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Chandan Healthcare and its competitors. Chandan Healthcare's current ROE % is 13.13%, which is 35% below median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandan Healthcare stock overvalued right now?
Chandan Healthcare (NSE:CHANDAN) has a current ROE % of 13.13%. The current ROE % is 13.13%, which is 35% below median its 10-year median of 20.10. Chandan Healthcare's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Chandan Healthcare (NSE:CHANDAN), the current ROE % is 13.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chandan Healthcare Ltd operates laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. The company operates single reportable business segment that is Diagnostics Services.
17GF Score
Get the complete analysis for NSE:CHANDAN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CHANDAN has been successfully added to your 
